178 related articles for article (PubMed ID: 36119082)
21. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
Sheshadri A; Goizueta AA; Shannon VR; London D; Garcia-Manero G; Kantarjian HM; Ravandi-Kashani F; Kadia TM; Konopleva MY; DiNardo CD; Pierce S; Zarifa A; Albittar AA; Zhong LL; Akhmedzhanov FO; Arain MH; Alfayez M; Alotaibi A; Altan M; Naing A; Mendoza TR; Godoy MCB; Shroff G; Kim ST; Faiz SA; Kontoyiannis DP; Khawaja F; Jennings K; Daver NG
Cancer; 2022 Jul; 128(14):2736-2745. PubMed ID: 35452134
[TBL] [Abstract][Full Text] [Related]
22. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
23. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
24. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
25. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis.
Moodabagil M; Easterling R; Peng J; Abu-Sbeih H; Meara A; Donnelly E; Owen DH; Ho K
Oncologist; 2024 Jun; ():. PubMed ID: 38886156
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
[TBL] [Abstract][Full Text] [Related]
27. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
[TBL] [Abstract][Full Text] [Related]
28. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
29. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
30. Cerebrospinal Fluid Interleukin-6 in Immune Checkpoint Inhibitor-Induced Autoimmune Meningoencephalitis.
Mizukami T; Masuda T; Kimura N; Uchida H; Jikumaru M; Hanaoka T; Matsubara E
Tohoku J Exp Med; 2022 Sep; 258(2):159-165. PubMed ID: 36047134
[TBL] [Abstract][Full Text] [Related]
31. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.
Huang Y; Fan H; Li N; Du J
Cancer Med; 2019 May; 8(5):2664-2674. PubMed ID: 30950194
[TBL] [Abstract][Full Text] [Related]
32. Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
Kashiwada T; Minegishi Y; Saito Y; Kato T; Atsumi K; Seike M; Kubota K; Terasaki Y; Gemma A
J Nippon Med Sch; 2019; 86(1):43-47. PubMed ID: 30918156
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
34. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab-Induced Organizing Pneumonia in Management of Non-small Cell Lung Carcinoma: A Case Report.
Habib T; Abu-Abaa M; Kolman-Taddeo D
Cureus; 2023 May; 15(5):e39217. PubMed ID: 37337505
[TBL] [Abstract][Full Text] [Related]
36. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
37. A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis.
Zhang Y; Li W; Hu X; Zhang J
Ann Palliat Med; 2021 Sep; 10(9):10083-10090. PubMed ID: 34551569
[TBL] [Abstract][Full Text] [Related]
38. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
Abdayem P; Planchard D
Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
[No Abstract] [Full Text] [Related]
39. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
40. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.
Inthasot V; Bruyneel M; Muylle I; Ninane V
Acta Clin Belg; 2020 Aug; 75(4):308-310. PubMed ID: 31179880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]